

- Mercadante S, Vitrano V, Catania V. Sexual issues in early and late stage cancer: a review. *Support Care Cancer* 2010;18:659–665.
- Hordern A, Street A. Issues of intimacy and sexuality in the face of cancer: the patient perspective. *Cancer Nurs* 2007;30:E11–E18.
- Bourgeois-Law G, Lotocki R. Sexuality and gynecological cancer: a needs assessment. *Can J Hum Sex* 1999;8:231–240.
- Feldman-Stewart D, Brundage MD, Hayter C, et al. What questions do patients with curable prostate cancer want answered? *Med Decis Making* 2000;20:7–19.
- Hordern AJ, Currow DC. A patient-centred approach to sexuality in the face of life-limiting illness. *Med J Aust* 2003;179:S8–S11.
- Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: barriers and recommendations. *Cancer J* 2009;15:74–77.
- Stead ML, Brown JM, Fallowfield L, et al. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. *Br J Cancer* 2003;88:666–671.
- Park ER, Bober SL, Campbell EG, et al. General internist communication about sexual function with cancer survivors. *J Gen Intern Med* 2009;24:S407–S411.
- American Cancer Society. *Cancer Facts & Figures 2013*. Atlanta: American Cancer Society, Inc.; 2013.
- Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. *JAMA* 2000;283:354–360.
- Helgason AR, Adolffson J, Dickman P, et al. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. *Br J Cancer* 1996;73:1417–1421.
- Litwin MS, Flanders SC, Padija DJ, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. *Urology* 1999;54:503–508.
- Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. *J Urol* 2005;173:1701–1705.
- Choi JM, Nelson CJ, Stasi J, et al. Orgasm associated incontinence (climacturia) following radical pelvic surgery: rates of occurrence and predictors. *J Urol* 2007;177:2223–2226.
- Guay A, Seftel AD. Sexual foreplay incontinence in men with erectile dysfunction after radical prostatectomy: a clinical observation. *Int J Impot Res* 2008;20:199–201.
- Nilsson AE, Carlsson S, Johansson E, et al. Orgasm-associated urinary incontinence and sexual life after radical prostatectomy. *J Sex Med* 2011;8:2632–2639.
- Mitchell SA, Jain RK, Laze J, et al. Post-prostatectomy incontinence during sexual activity: a single center prevalence study. *J Urol* 2011;186:982–985.
- Tal R, Valenzuela R, Aviv N, et al. Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. *J Sex Med* 2009;6:2813–2819.
- Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. *Eur Urol* 2006;50:711–718.
- Schover LR, Fouladi RT, Warneke CL, et al. Defining sexual outcomes after treatment for localized prostate carcinoma. *Cancer* 2002;95:1773–1785.
- Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. *J Urol* 1990;143:538–543.
- Namiki S, Ishidoya S, Ito A, et al. Quality of life after radical prostatectomy in Japanese men: a 5-Year follow up study. *Int J Urol* 2009;16:75–81.
- Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. *N Engl J Med* 2008;358:1250–1261.
- Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. *J Urol* 2000;163:1802–1807.
- Geary ES, Dendinger TE, Freiha FS, et al. Nerve sparing radical prostatectomy: a different view. *J Urol* 1995;154:145–149.
- Ayathurai R, Manoharan M, Nieder AM, et al. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. *BJU Int* 2008;101:833–836.
- Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. *J Urol* 2000;164:1929–1934.
- Michl UH, Friedrich MG, Graefen M, et al. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. *J Urol* 2006;176:227–231.
- Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. *J Urol* 2008;179:S40–S44.
- Kundu SD, Roehl KA, Eggner SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. *J Urol* 2004;172:2227–2231.
- Kimura M, Banez LL, Schroeck FR, et al. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. *J Sex Med* 2011;8:2935–2943.
- Namiki S, Kwan L, Kagawa-Singer M, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. *Prostate Cancer Prostatic Dis* 2008;11:298–302.
- Namiki S, Carlile RG, Namiki TS, et al. Racial differences in sexuality profiles among American, Japanese, and Japanese American men with localized prostate cancer. *J Sex Med* 2011;8:2625–2631.
- Fraiman MC, Lepor H, McCullough AR. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical retropubic prostatectomy. *Mol Urol* 1999;3:109–115.
- Contero P, Galzerano M, Bartoletti R, et al. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. *J Urol* 2007;178:602–607.
- Savoie M, Kim SS, Soloway MS. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. *J Urol* 2003;169:1462–1464.
- Munding MD, Wessells HB, Dalkin BL. Pilot study of changes in stretched penile length 3 months after radical retropubic prostatectomy. *Urology* 2001;58:567–569.
- Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. *Eur Urol* 2013;63:902–912.
- Zagaja GP, Mhoon DA, Aikens JE, et al. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. *Urology* 2000;56:631–634.
- Raina R, Lakin MM, Agarwal A, et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. *Urology* 2004;63:960–966.
- Blander DS, Sanchez-Ortiz RF, Wein AJ, et al. Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. *Int J Impot Res* 2000;12:165–168.
- Carvalho AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. *J Sex Med* 2012;9:2361–2369.
- Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature. *Eur J Med Res* 2002;7:435–446.
- Raina R, Lakin MM, Thukral M, et al. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. *Int J Impot Res* 2003;15:318–322.
- Dennis RL, McDougal WS. Pharmacological treatment of erectile dysfunction after radical prostatectomy. *J Urol* 1988;139:775–776.
- Baniel J, Israilov S, Segenreich E, et al. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. *BJU Int* 2001;88:58–62.
- Polito M, D'Anzeo G, Conti A, et al. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates. *BJU Int* 2012;110:E954–E957.
- Mulhall JP, Jahoda AE, Cairney M, et al. The causes of patient dropout from penile self-injection therapy for impotence. *J Urol* 1999;162:1291–1294.
- Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. *J Urol* 1998;160:1325–1328.
- Yuan J, Hoang AN, Romero CA, et al. Vacuum therapy in erectile dysfunction—science and clinical evidence. *Int J Impot Res* 2010;22:211–219.
- Pahlajani G, Raina R, Jones S, et al. Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. *J Sex Med* 2012;9:1182–1189.
- Raina R, Agarwal A, Ausmundson S, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. *Int J Impot Res* 2006;18:77–81.
- Stephenson RA, Mori M, Hsieh YC, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. *J Urol* 2005;174:646–650.
- Menard J, Tremoux JC, Faix A, et al. Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. *J Sex Med* 2011;8:3479–3486.
- Govier FE, Gibbons RP, Correa RJ, et al. Mechanical reliability, surgical complications, and patient and partner satisfaction of the modern three-piece inflatable penile prosthesis. *Urology* 1998;52:282–286.
- Mulhall JP, Ahmed A, Branch J, et al. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. *J Urol* 2003;169:1429–1433.
- Segal R, Burnett AL. Erectile preservation following radical prostatectomy. *Ther Adv Urol* 2011;3:35–46.
- Basal S, Wambi C, Acikel C, et al. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. *BJU Int* 2013;111:658–665.
- Engel JD. Effect on sexual function of a vacuum erection device post-prostatectomy. *Can J Urol* 2011;18:5721–5725.

60. Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Int J Impot Res* 2008;20:479-486.
61. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. *J Urol* 1997;158:1408-1410.
62. Muller A, Tal R, Donohue JF, et al. The effect of hyperbaric oxygen therapy on erectile function recovery in a rat cavernous nerve injury model. *J Sex Med* 2008;5:562-570.
63. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. *J Urol* 2004;171:771-774.
64. Albersen M, Joniau S, Claes H, et al. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. *Adv Urol* 2008;594868.
65. Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. *J Sex Med* 2005;2:532-540.
66. Brewer ME, Kim ED. Penile rehabilitation therapy with PDE-V inhibitors following radical prostatectomy: proceed with caution. *Adv Urol* 2009;852437.
67. Kaiho Y, Yamashita S, Arai Y. Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors. *Int J Urol* 2013;20:285-289.
68. Fode M, Ohl DA, Ralph D, et al. Penile rehabilitation after radical prostatectomy: what the evidence really says. *BJU Int* 2013;112:998-1008.
69. Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. *Eur Urol* 2012;62:273-286.
70. Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. *Eur Urol* 2008;54:924-931.
71. Bannowsky A, Van Ahlen H, Loch T. Increasing the dose of vardenafil on a daily basis does not improve erectile function after unilateral nerve-sparing radical prostatectomy. *J Sex Med* 2012;9:1448-1453.
72. Mulhall JP, Parker M, Waters BW, et al. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. *BJU Int* 2010;105:37-41.
73. Briganti A, Di Trapani E, Abdollah F, et al. Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. *J Sex Med* 2012;9:608-617.
74. Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. *Eur Urol* 2012;62:261-272.
75. Lips IM, Van Gils CH, Van Der Heide UA, et al. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. *BJU Int* 2009;103:762-767.
76. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst* 2004;96:1358-1367.
77. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. *J Urol* 2010;183:2206-2212.
78. Krahn MD, Bremner KE, Tomlinson G, et al. Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. *Prostate Cancer Prostatic Dis* 2009;12:361-368.
79. Yoshimura K, Arai Y, Ichioka K, et al. A 3-year prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy. *Prostate Cancer Prostatic Dis* 2004;7:144-151.
80. Dragicevic S, Naumovic T, Soldatovic I. Evaluation of health-related quality of life in patients with prostate cancer after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy. *Urol Int* 2010;85:173-179.
81. Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. *Cancer* 2012;118:4619-4626.
82. Mantz CA, Song P, Farhangi E, et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 1997;37:551-557.
83. Roeloffzen EM, Lips IM, Van Gellekom MP, et al. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer. *Int J Radiat Oncol Biol Phys* 2010;76:1054-1060.
84. Huyghe E, Delannes M, Wagner F, et al. Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2009;74:126-132.
85. Buron C, Le Vu B, Cosset JM, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. *Int J Radiat Oncol Biol Phys* 2007;67:812-822.
86. Huyghe E, Delaunay B, Njonnang Soh P, et al. Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer. *Int J Impot Res* 2013;25:121-126.
87. Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. *Oncology (Williston Park)* 2003;17:52-62.
88. Pahlajani G, Raina R, Jones JS, et al. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. *BJU Int* 2010;106:1524-1527.
89. Stember DS, Mulhall JP. The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer. *Brachytherapy* 2012;11:87-96.
90. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. *J Natl Cancer Inst* 2002;94:430-437.
91. Gacci M, Simonato A, Masieri L, et al. Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. *Health Qual Life Outcomes* 2009;7:94.
92. Litwin MS, Shpall AI, Dorey F, et al. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. *Am J Clin Oncol* 1998;21:327-332.
93. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. *Urology* 1997;49:207-216.
94. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. *J Urol* 2000;163:1743-1746.
95. Elliott S, Latini DM, Walker LM, et al. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. *J Sex Med* 2010;7:2996-3010.
96. Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. *J Urol* 2011;185:17-23.
97. Siddons HM, Wootten AC, Costello AJ. A randomised, wait-list controlled trial: evaluation of a cognitive-behavioural group intervention on psychosexual adjustment for men with localised prostate cancer. *Psychooncology* 2013 [Epub ahead of print].
98. Badr H, Krebs P. A systematic review and meta-analysis of psychosocial interventions for couples coping with cancer. *Psychooncology* 2013;22:1688-1704.
99. Beck AM, Robinson JW, Carlson LE. Sexual intimacy in heterosexual couples after prostate cancer treatment: What we know and what we still need to learn. *Urol Oncol* 2009;27:137-143.
100. Chambers SK, Pinnock C, Lepore SJ, et al. A systematic review of psychosocial interventions for men with prostate cancer and their partners. *Patient Educ Couns* 2011;85:e75-e88.
101. Chisholm KE, McCabe MP, Wootten AC, et al. Review: psychosocial interventions addressing sexual or relationship functioning in men with prostate cancer. *J Sex Med* 2012;9:1246-1260.
102. Parker WR, Montgomery JS, Wood DP Jr. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? *Curr Opin Urol* 2009;19:303-308.
103. Helgason AR, Fredrikson M, Adolffson J, et al. Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. *Int J Radiat Oncol Biol Phys* 1995;32:33-39.
104. Fergus KD, Gray RE, Fitch MI. Sexual dysfunction and the preservation of manhood: experiences of men with prostate cancer. *J Health Psychol* 2002;7:303-316.
105. Penson DF, Feng Z, Kuniyuki A, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. *J Clin Oncol* 2003;21:1147-1154.
106. Parker WR, Wang R, He C, et al. Five year expanded prostate cancer index composite-based quality of life outcomes after prostatectomy for localized prostate cancer. *BJU Int* 2011;107:585-590.
107. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. *J Sex Med* 2011;8:560-566.
108. Zhou ES, Penedo FJ, Bustillo NE, et al. Longitudinal effects of social support and adaptive coping on the emotional well-being of survivors of localized prostate cancer. *J Support Oncol* 2010;8:196-201.
109. Peltier A, Van Velthoven R, Roumequere T. Current management of erectile dysfunction after cancer treatment. *Curr Opin Oncol* 2009;21:303-309.
110. Wittmann D, Foley S, Balon R. A biopsychosocial approach to sexual recovery after prostate cancer surgery: the role of grief and mourning. *J Sex Marital Ther* 2011;37:130-144.
111. Walker LM, Robinson JW. Sexual adjustment to androgen deprivation therapy: struggles and strategies. *Qual Health Res* 2012;22:452-465.
112. Soloway CT, Soloway MS, Kim SS, et al. Sexual, psychological and dyadic qualities of the prostate cancer 'couple'. *BJU Int* 2005;95:780-785.
113. Zhou ES, Kim Y, Rasheed M, et al. Marital satisfaction of advanced prostate cancer survivors and their spousal caregivers: the dyadic effects of physical and mental health. *Psychooncology* 2011;20:1353-1357.
114. Badr H, Taylor CL. Sexual dysfunction and spousal communication in couples coping with prostate cancer. *Psychooncology* 2009;18:735-746.
115. Forbat L, White I, Marshall-Lucette S, et al. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. *BJU Int* 2012;109:98-103.
116. Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. *J Clin Oncol* 2012;30:3720-3725.
117. American Cancer Society. *Cancer Facts and Figures 2012*. Atlanta: American Cancer Society; 2012.

118. Carpentier MY, Fortenberry JD. Romantic and sexual relationships, body image, and fertility in adolescent and young adult testicular cancer survivors: a review of the literature. *J Adolesc Health* 2010;47:115–125.
119. Brodsky MS. Testicular cancer survivors' impressions of the impact of the disease on their lives. *Qual Health Res* 1995;5:78–96.
120. Kuczyk M, Machtens S, Bokemeyer C, et al. Sexual function and fertility after treatment of testicular cancer. *Curr Opin Urol* 2000;10:473–477.
121. Dahl AA, Bremnes R, Dahl O, et al. Is the sexual function compromised in long-term testicular cancer survivors? *Eur Urol* 2007;52:1438–1447.
122. Jonker-Pool G, Van De Wiel HB, Hoekstra HJ, et al. Sexual functioning after treatment for testicular cancer—review and meta-analysis of 36 empirical studies between 1975–2000. *Arch Sex Behav* 2001;30:55–74.
123. Rossen P, Pedersen AF, Zachariae R, et al. Sexuality and body image in long-term survivors of testicular cancer. *Eur J Cancer* 2012;48:571–578.
124. Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer: a systematic review. *J Psychosom Res* 2001;51:735–743.
125. Tuinman MA, Hoekstra HJ, Vidrine DJ, et al. Sexual function, depressive symptoms and marital status in nonseminoma testicular cancer patients: a longitudinal study. *Psychooncology* 2010;19:238–247.
126. Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual function and fertility after treatment of testicular cancer. *Br J Cancer* 1999;80:801–807.
127. Van Basten JP, Van Driel MF, Hoekstra HJ, et al. Objective and subjective effects of treatment for testicular cancer on sexual function. *BJU Int* 1999;84:671–678.
128. Eberhard J, Stahl O, Cohn-Cedermark G, et al. Sexual function in men treated for testicular cancer. *J Sex Med* 2009;6:1979–1989.
129. Fossa SD, Kravdal O. Fertility in Norwegian testicular cancer patients. *Br J Cancer* 2000;82:737–741.
130. Palermo G, Joris H, Devroey P, et al. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet* 1992;340:17–18.
131. Kim ED, Lamb DJ, Lipshultz LI. Intracytoplasmic sperm injection for treatment of the infertile male. *Tex Med* 1997;93:50–56.
132. Jonker-Pool G, Hoekstra HJ, Van Imhoff GW, et al. Male sexuality after cancer treatment—needs for information and support: testicular cancer compared to malignant lymphoma. *Patient Educ Couns* 2004;52:143–150.
133. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. *J Urol* 1999;162:77–81.
134. Hautmann RE. The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy. *Curr Opin Urol* 2009;19:522–526.
135. Gou X, Wang M, He WY, et al. Laparoscopic radical cystectomy for bladder cancer with prostatic and neurovascular sparing: initial experience. *Int Urol Nephrol* 2012;44:787–792.
136. Aboumarzouk OM, Hughes O, Narahari K, et al. Safety and feasibility of laparoscopic radical cystectomy for the treatment of bladder cancer. *J Endourol* 2013;27:1083–1095.
137. Keren Paz GE, Laudone VP, Bochner BH. Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery? *Curr Opin Urol* 2013;23:449–455.
138. Zippe CD, Raina R, Massanyi EZ, et al. Sexual function after male radical cystectomy in a sexually active population. *Urology* 2004;64:682–685.
139. Pan T, Zhou Y, Shen G, et al. Application of intrafascial neurovascular bundle spare technique in radical cystectomy. *Open Access J Urol* 2013;3:185–187.
140. Martis G, D'elia G, Diana M, et al. Prostatic capsule- and nerve-sparing cystectomy in organ-confined bladder cancer: preliminary results. *World J Surg* 2005;29:1277–1281.
141. Horenblas S, Meinhardt W, Ijzerman W, et al. Sexuality preserving cystectomy and neobladder: initial results. *J Urol* 2001;166:837–840.
142. Puppo P, Introini C, Bertolotto F, et al. Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer. *J Urol* 2008;179:1727–1732.
143. Hekal IA, El-Bahnasawy MS, Mosbah A, et al. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. *Eur Urol* 2009;55:275–283.
144. Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. *Urol Clin North Am* 2005;32:177–185.
145. Abdelhady M, Abusamra A, Pautler SE, et al. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. *BJU Int* 2007;99:326–329.
146. Stein JP, Hautmann RE, Penson D, et al. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. *Urol Oncol* 2009;27:466–472.
147. Hautmann RE, Hautmann O, Volkmer BG, et al. Nerve-sparing radical cystectomy: a new technique. *Eur Urol Suppl* 2010;9:428–432.
148. Richards KA, Parks GE, Badlani GH, et al. Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens. *Urology* 2010;75:1116–1120.
149. Weizer AZ, Shah RB, Lee CT, et al. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. *Urol Oncol* 2007;25:460–464.
150. Sagalowsky AL. Commentary on clinical outcomes of sexuality preserving cystectomy and neobladder. *J Urol* 2008;179:S39.
151. Bjerre BD, Johansen C, Steven K. A questionnaire study of sexological problems following urinary diversion in the female patient. *Scand J Urol Nephrol* 1997;31:155–160.
152. Takenaka A, Hara I, Soga H, et al. Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years. *Int Urol Nephrol* 2011;43:749–754.
153. Mosbah A, El Bahnasawy M, Osman Y, et al. Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: a prospective randomized study. *J Sex Med* 2011;8:2106–2111.
154. Van Der Aa MN, Bekker MD, Van Der Kwast TH, et al. Sexual function of patients under surveillance for bladder cancer. *BJU Int* 2009;104:35–40.
155. Stenzl A, Colleselli K, Poisel S, et al. Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. *J Urol* 1995;154:2044–2049.
156. Clifton MM, Tollefson MK. Anatomic basis of radical cystectomy and orthotopic urinary diversion in female patients. *Clin Anat* 2013;26:105–109.
157. Bhatt A, Nandipati K, Dhar N, et al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. *Urology* 2006;67:742–745.
158. El-Bahnasawy MS, Osman Y, El-Hefnawy A, et al. Radical cystectomy and urinary diversion in women: impact on sexual function. *Scand J Urol Nephrol* 2011;45:332–338.
159. Zippe CD, Raina R, Shah AD, et al. Female sexual dysfunction after radical cystectomy: a new outcome measure. *Urology* 2004;63:1153–1157.
160. Kubler H, Gschwend JE. Ileal neobladder in women with bladder cancer: cancer control and functional aspects. *Curr Opin Urol* 2011;21:478–482.
161. Ali-El-Dein B, Mosbah A, Osman Y, et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. *Eur J Surg Oncol* 2013;39:358–364.
162. Elaffandi AH, Khalil HH, Aboul Kassem HA, et al. Vaginal reconstruction with a greater omentum-pedicled graft combined with a vicryl mesh after anterior pelvic exenteration. Surgical approach with long-term follow-up. *Int J Gynecol Cancer* 2007;17:536–542.
163. Bjordal K, De Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. *Eur J Cancer* 2000;36:1796–1807.
164. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091–2098.
165. El-Deiry M, Funk GF, Nalwa S, et al. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2005;131:879–885.
166. O'Brien K, Roe B, Low C, et al. An exploration of the perceived changes in intimacy of patients' relationships following head and neck cancer. *J Clin Nurs* 2012;21:2499–2508.
167. Costa EF, Nogueira TE, De Souza Lima NC, et al. A qualitative study of the dimensions of patients' perceptions of facial disfigurement after head and neck cancer surgery. *Spec Care Dentist* 2014;34:114–121.
168. Low C, Fullarton M, Parkinson E, et al. Issues of intimacy and sexual dysfunction following major head and neck cancer treatment. *Oral Oncol* 2009;45:898–903.
169. Gamba A, Romano M, Grosso IM, et al. Psychosocial adjustment of patients surgically treated for head and neck cancer. *Head Neck* 1992;14:218–223.
170. Gritz ER, Carmack CL, De Moor C, et al. First year after head and neck cancer: quality of life. *J Clin Oncol* 1999;17:352–360.
171. Singer S, Danker H, Dietz A, et al. Sexual problems after total or partial laryngectomy. *Laryngoscope* 2008;118:2218–2224.
172. Meyers AD, Aarons B, Suzuki B, et al. Sexual behavior following laryngectomy. *Ear Nose Throat J* 1980;59:327–329.
173. Moreno KF, Khabbaz E, Gaitonde K, et al. Sexuality after treatment of head and neck cancer: findings based on modification of sexual adjustment questionnaire. *Laryngoscope* 2012;122:1526–1531.
174. Monga U, Tan C, Ostermann HJ, et al. Sexuality in head and neck cancer patients. *Arch Phys Med Rehabil* 1997;78:298–304.
175. De Boer MF, Pruyn JF, Van Den Borne B, et al. Rehabilitation outcomes of long-term survivors treated for head and neck cancer. *Head Neck* 1995;17:503–515.
176. Oskam IM, Verdonck-De Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. *Oral Oncol* 2013;49:443–448.
177. Kangas M, Milross C, Taylor A, et al. A pilot randomized controlled trial of a brief early intervention for reducing posttraumatic stress disorder, anxiety and depressive symptoms in newly diagnosed head and neck cancer patients. *Psychooncology* 2013;22:1665–1673.
178. Jenewein J, Zwahlen RA, Zwahlen D, et al. Quality of life and dyadic adjustment in oral cancer patients and their female partners. *Eur J Cancer Care (Engl)* 2008;17:127–135.
179. Chatterjee R, Kottaridis PD, McGarrigle HH, et al. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for hematological malignancies. *Bone Marrow Transplant* 2002;29:607–610.
180. Humphreys CT, Tallman B, Altmaier EM, et al. Sexual functioning in patients undergoing bone marrow transplantation: a longitudinal study. *Bone Marrow Transplant* 2007;39:491–496.

181. Syrjala KL, Kurland BF, Abrams JR, et al. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. *Blood* 2008;111:989-996.
182. Spinelli S, Chioldi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. *Haematologica* 2003;88:1163-1168.
183. Zantoni D, Grigg AP, Macgregor L, et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. *Bone Marrow Transplant* 2006;38:567-572.
184. Hirsch P, Leclerc M, Rybojad M, et al. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. *Transplantation* 2012;93:1265-1269.
185. Havenga K, Maas CP, Deruiter MC, et al. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. *Semin Surg Oncol* 2000;18:235-243.
186. Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. *Cancer Control* 2010;17:44-51.
187. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol* 2007;25:3061-3068.
188. Lindsey I, George B, Kettlewell M, et al. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. *Dis Colon Rectum* 2002;45:727-732.
189. Sprunk E, Alteneider RR. The impact of an ostomy on sexuality. *Clin J Oncol Nurs* 2000;4:85-88.
190. Bloom JR, Stewart SL, Chang S, et al. Then and now: quality of life of young breast cancer survivors. *Psychooncology* 2004;13:147-160.
191. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. *J Natl Cancer Inst* 2004;96:376-387.
192. Devita VT, Rosenberg SA, Hellman S. *Cancer: Principles and Practices of Oncology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
193. Andersen BL. Surviving cancer: the importance of sexual self-concept. *Med Pediatr Oncol* 1999;33:15-23.
194. Fobair P, Stewart SL, Chang S, et al. Body image and sexual problems in young women with breast cancer. *Psychooncology* 2006;15:579-594.
195. Den Ouden BL, Van Heck, Guus L, et al. Clinical Factors are not the best predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. *Psychooncology* 2009;19:646-656.
196. Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. *J Sex Med* 2010;7:349-373.
197. Fobair P, Spiegel D. Concerns about sexuality after breast cancer. *Cancer J* 2009;15:19-26.
198. Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. *Ann Oncol* 1997;8:149-153.
199. Burwell SR, Case LD, Kaelin C, et al. Sexual problems in younger women after breast cancer surgery. *J Clin Oncol* 2006;24:2815-2821.
200. Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. *Am J Med* 2005;118:136-141.
201. Arora NK, Gustafson DH, Hawkins RP, et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. *Cancer* 2001;92:1288-1298.
202. Figueiredo MI, Cullen J, Hwang YT, et al. Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health? *J Clin Oncol* 2004;22:4002-4009.
203. Pockaj BA, Degnim AC, Boughey JC, et al. Quality of life after breast cancer surgery: What have we learned and where should we go next? *J Surg Oncol* 2009;99:447-455.
204. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. *Health Psychol* 1997;16:284-298.
205. Schlenz I, Kuzbari R, Gruber H, et al. The sensitivity of the nipple-areola complex: an anatomic study. *Plast Reconstr Surg* 2000;105:905-909.
206. Djohan R, Gage E, Catherwright J, et al. Patient satisfaction following nipple-sparing mastectomy and immediate breast reconstruction: an 8-year outcome study. *Plast Reconstr Surg* 2010;125:818-829.
207. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. *J Clin Oncol* 2008;26:753-758.
208. Leining MG, Gelber S, Rosenberg R, et al. Menopausal-type symptoms in young breast cancer survivors. *Ann Oncol* 2006;17:1777-1782.
209. Greendale GA, Petersen L, Zibecchi L, et al. Factors related to sexual function in postmenopausal women with a history of breast cancer. *Menopause* 2001;8:111-119.
210. Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. *J Natl Cancer Inst* 2007;99:672-679.
211. Buijs C, De Vries EG, Mourits MJ, et al. The influence of endocrine treatments for breast cancer on health-related quality of life. *Cancer Treat Rev* 2008;34:640-655.
212. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Clin Oncol* 1999;17:2659-2669.
213. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2742-2751.
214. Biri A, Korucuoglu U, Ilhan MN, et al. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women. *Arch Gynecol Obstet* 2009;279:505-509.
215. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. *N Engl J Med* 2003;348:2431-2442.
216. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. *Breast Cancer Res Treat* 2006;100:273-284.
217. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. *Breast* 2008;17:436-440.
218. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. *J Natl Cancer Inst* 2000;92:1054-1064.
219. Scott JL, Kayser K. A review of couple-based interventions for enhancing women's sexual adjustment and body image after cancer. *Cancer J* 2009;15:48-56.
220. Ratner ES, Foran KA, Schwartz PE, et al. Sexuality and intimacy after gynecological cancer. *Maturitas* 2010;66:23-26.
221. Carmack Taylor CL, Basen-Engquist K, Shinn EH, et al. Predictors of sexual functioning in ovarian cancer patients. *J Clin Oncol* 2004;22:881-889.
222. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:2792-2797.
223. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med* 1999;340:1383-1389.
224. Jensen PT, Groenvold M, Klee MC, et al. Early-stage cervical carcinoma, radical hysterectomy, and sexual function. A longitudinal study. *Cancer* 2004;100:97-106.
225. Jensen PT, Groenvold M, Klee MC, et al. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 2003;56:937-949.
226. Green MS, Naumann RW, Elliot M, et al. Sexual dysfunction following vulvectomy. *Gynecol Oncol* 2000;77:73-77.
227. Likes WM, Stegbauer C, Tillmanns T, et al. Correlates of sexual function following vulvar excision. *Gynecol Oncol* 2007;105:600-603.
228. Katz A. Interventions for sexuality after pelvic radiation therapy and gynecological cancer. *Cancer J* 2009;15:45-47.
229. Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 1999;44:497-506.
230. Brotto LA, Heiman JR, Goff B, et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. *Arch Sex Behav* 2008;37:317-329.
231. Schroder M, Mell LK, Hurteau JA, et al. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. *Int J Radiat Oncol Biol Phys* 2005;61:1078-1086.
232. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117-1130.
233. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2004;22:1055-1062.
234. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol* 2008;26:1331-1337.
235. Matloff ET, Barnett RE, Bober SL. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers. *Cancer J* 2009;15:15-18.
236. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2005;23:7804-7810.
237. Roberts CS, Turney ME, Knowles AM. Psychosocial issues of adolescents with cancer. *Soc Work Health Care* 1998;27:3-18.
238. Tromp K, Claessens JJ, Knijnenburg SL, et al. Reproductive status in adult male long-term survivors of childhood cancer. *Hum Reprod* 2011;26:1775-1783.
239. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol* 2009;27:2677-2685.
240. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2010;28:332-339.

241. Jacobs LA, Pucci DA. Adult survivors of childhood cancer: the medical and psychosocial late effects of cancer treatment and the impact on sexual and reproductive health. *J Sex Med* 2013;10:120–126.
242. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:3408–3416.
243. Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. *J Clin Oncol* 2009;27:2390–2395.
244. Van Dijk EM, Van Dulmen-Den Broeder E, Kaspers GJ, et al. Psychosexual functioning of childhood cancer survivors. *Psychooncology* 2008;17:506–511.
245. Sundberg KK, Lampic C, Arvidson J, et al. Sexual function and experience among long-term survivors of childhood cancer. *Eur J Cancer* 2011;47:397–403.
246. Hall AE, Boyes AW, Bowman J, et al. Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors. *Support Care Cancer* 2012;20:1333–1341.
247. Bober SL, Zhou ES, Chen B, et al. Sexual function in childhood cancer survivors: a report from Project REACH. *J Sex Med* 2013;10:2084–2093.
248. Zebrack BJ, Foley S, Wittmann D, et al. Sexual functioning in young adult survivors of childhood cancer. *Psychooncology* 2010;19:814–822.
249. Morgan S, Davies S, Palmer S, et al. Sex, drugs, and rock 'n' roll: caring for adolescents and young adults with cancer. *J Clin Oncol* 2010;28:4825–4830.
250. Kelly D. Developing age appropriate psychosexual support for adolescent cancer survivors: a discussion paper. *J Sex Med* 2013;10:133–138.
251. Zebrack B. Information and service needs for young adult cancer survivors. *Support Care Cancer* 2009;17:349–357.
252. Canada AL, Schover LR, Li Y. A pilot intervention to enhance psychosexual development in adolescents and young adults with cancer. *Pediatr Blood Cancer* 2007;49:824–828.
253. Miedema B, Easley J, Robinson LM. Do current cancer follow-up care practices meet the needs of young adult cancer survivors in Canada? A qualitative inquiry. *Curr Oncol* 2013;20:14–22.
254. Van Den Berg H, Langeveld NE. Parental knowledge of fertility in male childhood cancer survivors. *Psychooncology* 2008;17:287–291.
255. Schover LR. Patient attitudes toward fertility preservation. *Pediatr Blood Cancer* 2009;53:281–284.
256. Johnson RH, Kroon L. Optimizing fertility preservation practices for adolescent and young adult cancer patients. *J Natl Compr Canc Netw* 2013;11:71–77.
257. American Cancer Society. *Cancer Facts & Figures for African-Americans 2012-2013*. Atlanta: American Cancer Society; 2012.
258. American Cancer Society. *Cancer Facts & Figures for Hispanics/Latinos 2012-2014*. Atlanta: American Cancer Society; 2012.
259. Krahe B. Sexual scripts and heterosexual aggression. In: Eckes T, Trautner HM, eds. *The Developmental Social Psychology of Gender*. New Jersey: LEA; 2000: 273–292.
260. Matlin MW. *The Psychology of Women*. Toronto, ON: Thomson Wadsworth; 2004.
261. Jenkins R, Schover LR, Fouladi RT, et al. Sexuality and health-related quality of life after prostate cancer in African-American and white men treated for localized disease. *J Sex Marital Ther* 2004;30:79–93.
262. Johnson TK, Gilliland FD, Hoffman RM, et al. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. *J Clin Oncol* 2004;22:4193–4201.
263. Wilmoth MC, Sanders LD. Accept me for myself: African American women's issues after breast cancer. *Oncol Nurs Forum* 2001;28:875–879.
264. Giedzinska AS, Meyerowitz BE, Ganz PA, et al. Health-related quality of life in a multiethnic sample of breast cancer survivors. *Ann Behav Med* 2004;28:39–51.
265. Wyatt GE, Desmond KA, Ganz PA, et al. Sexual functioning and intimacy in African American and white breast cancer survivors: a descriptive study. *Womens Health* 1998;4:385–405.
266. Taylor KL, Lamdan RM, Siegel JE, et al. Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients. *Psychooncology* 2002;11:505–517.
267. Schover LR, Jenkins R, Sui D, et al. Randomized trial of peer counseling on reproductive health in African American breast cancer survivors. *J Clin Oncol* 2006;24:1620–1626.
268. Ashing-Giwa KT, Kagawa-Singer M, Padilla GV, et al. The impact of cervical cancer and dysplasia: a qualitative, multiethnic study. *Psychooncology* 2004;13:709–728.
269. Okazaki S. Influences of culture on Asian Americans' sexuality. *J Sex Res* 2002;39:34–41.
270. Ashing-Giwa KT. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. *J Cancer Surviv* 2008;2:215–223.
271. Khoo SB. Impact of cancer on psychosexuality: cultural perspectives of Asian women. *Int J Nurs Pract* 2009;15:481–488.
272. Stanton AL, Estes MA, Estes NC, et al. Treatment decision making and adjustment to breast cancer: a longitudinal study. *J Consult Clin Psychol* 1998;66:313–322.
273. Wimberly SR, Carver CS, Laurenceau JP, et al. Perceived partner reactions to diagnosis and treatment of breast cancer: impact on psychosocial and psychosexual adjustment. *J Consult Clin Psychol* 2005;73:300–311.
274. Boehmer U, Clark JA. Communication about prostate cancer between men and their wives. *J Fam Pract* 2001;50:226–234.
275. Rivers BM, August EM, Gwede CK, et al. Psychosocial issues related to sexual functioning among African-American prostate cancer survivors and their spouses. *Psychooncology* 2011;20:106–110.
276. Shifren JL, Avis NE. Surgical menopause: effects on psychological well-being and sexuality. *Menopause* 2007;14:586–591.
277. Couper J, Bloch S, Love A, et al. Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature. *Psychooncology* 2006;15:937–953.
278. Rowland JH, Meyerowitz BE, Crespi CM, et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. *Breast Cancer Res Treat* 2009;118:99–111.
279. Manne S, Badr H. Intimacy and relationship processes in couples' psychosocial adaptation to cancer. *Cancer* 2008;112:2541–2555.
280. Mick J, Hughes M, Cohen MZ. Using the BETTER Model to assess sexuality. *Clin J Oncol Nurs* 2004;8:84–86.
281. Jeffery DD, Tzeng JP, Keefe FJ, et al. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. *Cancer* 2009;115:1142–1153.
282. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care* 1998;36:1002–1012.
283. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997;49:822–830.
284. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000;26:191–208.
285. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. *N Engl J Med* 2004;350:482–492.
286. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. *J Urol* 2013;190:639–644.
287. Leibowitz RL, Dorff TB, Tucker S, et al. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. *BJU Int* 2009;105:1397–1401.
288. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. *J Urol* 2013;189:826–833.
289. Corona G, Rastrelli G, Forti G, et al. Update in testosterone therapy for men. *J Sex Med* 2011;8:639–654.
290. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. *J Clin Oncol* 1997;15:969–973.
291. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. *Menopause* 2007;14:355–369.
292. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 2005;365:60–62.
293. Krychman ML, Katz A. Breast cancer and sexuality: multi-modal treatment options. *J Sex Med* 2012;9:5–13.
294. Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. *Menopause* 2012;19:109–117.
295. Basson R. Pharmacotherapy for women's sexual dysfunction. *Expert Opin Pharmacother* 2009;10:1631–1648.
296. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst* 2002;94:606–616.
297. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. *J Natl Cancer Inst* 2002;94:39–49.
298. Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. *Climacteric* 2014;17:173–182.
299. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. *Maturitas* 2013;74(3):220–225.
300. Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. *Menopause* 2013;20:418–427.
301. Loprinzi CL, Wolf SL, Barton DL, et al. Symptom management in premenopausal patients with breast cancer. *Lancet Oncol* 2008;9:993–1001.